Title: Seoul Economy – NeoPharm completed clinical trial of medicine for Psoriasis in the United States

Publication: Seoul Economy

Date: 10 April 2012

Summary

• NeoPharm developed a medicinal substance for psoriasis called ‘ADfence-P’ through joint research with LegoChem Biosciences and conducted clinical study with the US clinical institution specialized in skin evaluation, AMA Laboratories, INC. According to the results, ADfense-P makes as much improvement as prescribed medicine.

   

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).